Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of AMG 416 in secondary hyperparathyroidism in hemodialysis patients
NL-OMON41088Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Mar 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etelcalcetide in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Primary endpoint: Long-term safety and tolerability of AMG 416. Started Mar 2015; status: active, not recruiting.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NL-OMON41088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41088.